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Ghent Fertility and Stem Cell Team (G-FaST), Department for Reproductive Medicine, Ghent University Hospital, Ghent,
Belgium.Objective: To investigate the extent to which assisted oocyte activation (AOA) improves clinical outcomes in patients diagnosed with
oocyte activation deﬁciencies (OADs).
Design: Retrospective cohort study comparing AOA cycles and previous intracytoplasmic sperm injection (ICSI) cycles in couples expe-
riencing low or total failed fertilization after ICSI. Importantly, the sperm-related oocyte-activating capacity was examined in all
patients before AOA with the use of the mouse oocyte activation test (MOAT).
Setting: Infertility center at a university hospital.
Patient(s): A total of 122 couples with a history of low or total failed fertilization after ICSI.
Intervention(s): ICSI, MOAT, AOA, and embryo transfer.
Main Outcome Measure(s): Fertilization, pregnancy, and live birth rates.
Result(s): MOAT revealed 19 patients with a sperm-related OAD (MOAT group 1), 56 patients with a diminished sperm-related oocyte-
activating capacity (MOAT group 2), and 47 patients with a suspected oocyte-related OAD (MOAT group 3). AOA (191 cycles)
signiﬁcantly improved fertilization, pregnancy, and live birth rates in all MOAT groups compared with previous ICSI attempts (243
cycles). Fertilization rates after AOA were signiﬁcantly different among MOAT groups 1 (70.1%), 2 (63.0%), and 3 (57.3%). Between
MOAT group 1 and 3, signiﬁcant differences in pregnancy (49.0% vs. 29.4%) and live birth (41.2% vs. 22.1%) rates were observed.
In total, 225 embryo transfers resulted in 60 healthy live births following AOA.
Conclusion(s): Patients undergoing diagnostic testing before AOA show a signiﬁcant improvement in clinical outcomes compared
with previous cycles. Our ﬁndings highlight that AOA should be reserved for patients with clear OADs. (Fertil Steril 2019;112:
266–74. 2019 by American Society for Reproductive Medicine.)
El resumen está disponible en Español al ﬁnal del artículo.
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Fertility and Sterility®I ntracytoplasmic sperm injection (ICSI) has become themost popular assisted reproductive technique applied forseveral infertility indications (1). Although normal fertil-
ization rates are estimated at 70%, total fertilization failure
(TFF) still occurs in 3%–5% of all ICSI cycles (2). The main
cause for TFF after ICSI has been attributed to oocyte activa-
tion deﬁciencies (OADs), which can be related to sperm or
oocyte factors (3, 4).
Oocyte activation is a universal process comprising a
complex series of molecular events that are essential for fertil-
ization (5). The initiation of the oocyte activation process is
triggered by a sperm oocyte-activating factor, phospholipase
C zeta (PLCz), which is delivered into the oocyte at sperm-egg
fusion (6). In mammals, a typical pattern of multiple calcium
(Ca2þ) increases, namely Ca2þ oscillations, is observed after
the fusion of the sperm and the oocyte. These Ca2þ oscilla-
tions are required to achieve the resumption of the meiotic
cell cycle and ultimately successful fertilization (3). Both the
sperm and the oocyte play important roles: the sperm by sup-
plying its functional sperm factor PLCz and the mature oocyte
by being receptive to PLCz and generating the correct Ca2þ
pattern.
The use of ICSI in combination with assisted oocyte acti-
vation (AOA) has gained popularity over the past two decades
as a treatment for patients experiencing fertilization failure
after ICSI (3, 4, 7, 8). AOA aims to provide a sufﬁcient
intracellular Ca2þ release, allowing successful oocyte
activation and fertilization (4, 9). The AOA technique is a
procedure by which Ca2þ rises are artiﬁcially induced in the
oocyte, with Ca2þ ionophores being the most commonly
applied technique (3). However, there is currently no clinical
consensus regarding the appropriate AOA treatment
protocol. Moreover, patients are commonly treated without
a clear indication. For example, Borges et al. (2009)
performed AOA in the ﬁrst ICSI cycle for abnormalities in
sperm morphology without prior diagnosis of the cause of
failed fertilization (10). As such, clinics do not achieve
consistent outcomes (i.e., extensive variability in
fertilization rates) and often do not observe a direct beneﬁt
of AOA (11). Moreover, the use of particular artiﬁcial
activation agents remains controversial. We have previously
shown that calcimycin (GM508 Cult-Active), used by many
IVF laboratories to overcome fertilization failure, is signiﬁ-
cantly less efﬁcient compared with ionomycin-based AOA
(12).
Two decades ago, we developed a diagnostic method to
evaluate the oocyte-activating capacity of human spermato-
zoa (8, 13): the mouse oocyte activation test (MOAT), which
has also been performed by other centers (14–16). In
accordance with the MOAT result, patients are diagnosed
with sperm-related OAD (MOAT group 1), diminished
oocyte-activating capacity of the sperm (MOAT group 2), or
suspected oocyte-related OAD (MOAT group 3) (8). Impor-
tantly, MOAT serves as a valuable tool for appropriate patient
counseling, particularly regarding gamete donation. More-
over, because studies have shown that OADs may have an un-
derlying genetic cause, such as mutations in the PLCz gene
(17), patients can be further informed about risks of OAD
transmission to children born after AOA.VOL. 112 NO. 2 / AUGUST 2019To date, large-scale studies assessing the efﬁciency of
AOA in patients experiencing TFF or low fertilization (LF;
<33%) after ICSI with prior diagnostic testing for an OAD
are lacking. Here, we performed a retrospective cohort study,
including patients with previous TFF or LF after ICSI, for
whom the sperm-related oocyte-activating capacity was
examined by MOAT before AOA treatment. Moreover, we
investigated to what extent AOA improved clinical outcomes
in patients diagnosed with OADs.MATERIALS AND METHODS
Study Design, Setting, and Participants
A retrospective cohort study was performed, including 122
couples with a history of TFF (fertilization rate of 0%–10%)
or LF (fertilization rate of%33.3%, based on the 5th percen-
tile of mean fertilization rates) after conventional ICSI. The
sperm-related oocyte-activating capacity of all patients was
examined by means of MOAT, performed from January
2001 to December 2017 at the research facility at Ghent Uni-
versity Hospital. All patients underwent AOA from April 2001
to April 2018 at the IVF facility at Ghent University Hospital.Sperm Preparation
Both frozen-thawed and fresh human ejaculated sperm sam-
ples were washed by means of centrifugation (1600 rpm,
10 minutes) with Sydney IVF Gamete Buffer (Cook). For clin-
ical cycles (ICSI or ICSI-AOA), standard sperm selection was
performed with the use of density-gradient centrifugation,
whereas for MOAT, the swim-out sperm selection procedure
was carried out for all sperm samples unless a very low sperm
count was observed. Only motile sperm were recovered and
mechanically immobilized before ICSI.MOAT Procedure
MOAT was performed on all patients as previously described
(18). Brieﬂy, mature mouse oocytes were collected from
superovulated B6D2F1 hybrid female mice (Janvier Labs)
and cultured in KSOM media.
Four different groups were required to execute a complete
test: 1) injection of at least 40 oocytes with patient spermato-
zoa; 2) injection of at least 40 oocytes with control (research-
donated) spermatozoa with proven fertilization capacity
(positive control); 3) sham injection of at least 10 oocytes (me-
dium injection without spermatozoa; negative control); and
4) at least 10 medium control oocytes (nonmanipulated
mouse oocytes; negative control). Injections were performed
at 5–10 C in HEPES-buffered KSOM, 20% fetal bovine serum
(Gibco) with the use of piezoelectric pulses.
After micromanipulations, oocytes were cultured in
KSOM and checked for two-cell formation (activation rate)
24 hours later. Depending on the activation rate, patients
were classiﬁed into MOAT group 1 (%20% activation, i.e.,
the upper limit of the negative control), MOAT group 2
(21%–84% activation), or MOAT group 3 (R85% activation,
i.e., the lower limit of the positive control) (8). All cultures
were performed at 37C in 6% CO2, 5% O2, and 89% N2.267
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Many patients undergoing MOAT and AOA are referred to our
center from other IVF clinics (75%) where they experienced
TFF or LF after ICSI. As such, we do not possess all the infor-
mation regarding the stimulation protocols of their previous
ICSI cycles. In the majority of the AOA cycles, a short agonist
treatment was chosen for controlled ovarian stimulation;
however, in 5% and 16% of the AOA cycles, a long agonist
or antagonist protocol was chosen, respectively. Ovulation
was triggered by administering hCG. We delayed our interval
of denudation because all AOA pick-ups were planned as
early as possible and denudation only occurred just before
the AOA.AOA Procedure
Thirty-six hours after hCG administration, oocytes were
retrieved by means of transvaginal ultrasound–guided punc-
ture of the ovarian follicles in HTF-HEPES medium (Origio).
Cumulus-oocyte complexes were brieﬂy exposed to hyal-
uronidase (Cumulase; Origio) followed by mechanical denu-
dation. Subsequently, oocytes were cultured in Sydney IVF
Fertilization Medium (Cook).
The AOA procedure was performed as previously
described (8). Brieﬂy, freshly collected mature oocytes were
injected with patients' spermatozoa along with 0.1 mol/L
CaCl2 (Sigma-Aldrich), corresponding to the diameter of the
oocyte (19). After a 30-minute incubation period, oocytes un-
derwent a twofold exposure to ionomycin (10 mmol/L, I9657;
Sigma-Aldrich) for 10 minutes with a 30-minute interval
before culture. Embryos were cultured in Sydney IVF Cleav-
age Medium (Cook) until day 3 (D3) and in Sydney IVF Blas-
tocyst Medium (Cook) from D3 to D5.Embryo Grading
Embryos were classiﬁed into four quality categories in accor-
dance with European Society for Human Reproduction and
Embryology guidelines (20) (Supplemental Table 1;
Supplemental Tables 1–5 are available online at www.
fertstert.org).Embryo Transfer
Embryo transfers (ETs) were performed on D2, D3, or D5.
Criteria for ETs changed during the study period. Before
2012, ETs were predominately performed on D2 or D3. In
2012 and 2013, ETs were performed on D5 when at least
ten diploid zygotes were obtained, otherwise on D3. In 2014
and 2015, the number of diploid zygotes required for a D5
ET was reduced to ﬁve. From 2016 on, only D5 ETs were per-
formed, regardless of the number of zygotes.Study Outcomes
In accordance with the MOAT result, AOA efﬁciency was
determined based on fertilization, pregnancy, and live birth
rates compared with previous conventional ICSI cycle out-
comes. Information regarding previous ICSI cycles was ob-
tained from the IVF facility at Ghent University Hospital268and other IVF centers both internationally and within
Belgium.Statistics
The chi-square test, Kruskal-Wallis test, and Mann-Whitney
U test were used for statistical analysis with the use of the
Statistical Package for Social Sciences (SPSS Statistics 25;
IBM), as appropriate. P values < .05 were considered to be
statistically signiﬁcant.Study Approval
Written informed consent for the MOAT and AOA treatment
was obtained from every couple (B670201423110). The
use of laboratory animals for performing the MOAT was
approved by the Ghent University Hospital Ethical Committee
for Laboratory Animals (ECD no. 15/55).
RESULTS
Participants
In total, 122 couples with a history of TFF or LF after ICSI (243
ICSI cycles) were included in the study. A mean of 7.8 oocytes
per cycle were injected with motile sperm in previous ICSI at-
tempts, with an unknown underlying cause of fertilization
failure (21, 22). The mean maternal ages among the
different MOAT groups were 31.2 years, 33.9 years, and
33.7 years for MOAT groups 1, 2, and 3, respectively. All
couples underwent conventional ICSI, MOAT, and AOA,
except for seven patients in MOAT group 1 who did not
undergo conventional ICSI after the diagnosis of
globozoospermia. The mean time between the MOAT and
subsequent AOA treatment was 13.4  9.4 weeks and that
between ICSI and AOA, 39.7  27.0 weeks.MOAT Distribution
The MOAT revealed 19 patients with a sperm-related OAD
(MOAT group 1), 56 patients with a diminished oocyte-
activating capacity of the sperm (MOAT group 2), and 47 pa-
tients with a presumably oocyte-related OAD (MOAT group
3). Except for one patient with another type of teratozoosper-
mia, all MOAT group 1 patients were diagnosed by means of
routine semen analysis with partial (n ¼ 1) or total (n ¼ 17)
globozoospermia. Semen parameters for all MOAT groups
are presented in Supplemental Table 2.AOA Outcome
In total, 191 AOA cycles were performed at our center from
April 2001 to April 2018. The overall fertilization rate after
AOA treatment was 63.3% (1,104/1,743), which was signiﬁ-
cantly higher than previous ICSI attempts, 15.2% (286/
1,884; P< .001). Fertilization rates increased signiﬁcantly
from 9.7%, 14.8%, and 17.7% after conventional ICSI to
70.1%, 63.0%, and 57.3% after AOA in MOAT groups 1, 2,
and 3, respectively (P< .001; Table 1). After AOA treatment,
MOAT group 1 patients showed signiﬁcantly higher fertiliza-
tion rates compared with MOAT group 2 patients (P¼ .01),
which had a signiﬁcantly higher fertilization rate thanVOL. 112 NO. 2 / AUGUST 2019
TABLE 1
Comparison of preimplantation characteristics and embryo transfer outcomes after previous ICSI and subsequent AOA treatment within and
between the different MOAT groups, comprising patients with previous low or total failed fertilization after conventional ICSI.
Parameter
MOAT group
1 (n[ 19)
MOAT group
2 (n[ 56)
MOAT group
3 (n[ 47)
Treatment (oocyte
retrievals)
ICSI (n ¼ 20) AOA (n ¼ 35) ICSI (n ¼ 140) AOA (n ¼ 89) ICSI (n ¼ 83) AOA (n ¼ 67)
Cumulus-oocyte
complexes
246 572 1414 1129 816 650
Fertilization rate
(2PN/MII)
9.7% (18/185)a 70.1% (330/471)b 14.8% (163/1,104)a,c 63.0% (500/794)d 17.7% (105/595)c 57.3% (274/478)e
Fresh ET 9 34 68 65 40 53
Mean fresh embryos
transferred
0.6  0.8 1.5  0.7 0.6  0.7 1.1  0.9 0.6  0.7 1.2  0.8
Embryos
cryopreserved
2 113 11 132 6 59
Frozen ET 0 17 3 41 3 15
Mean frozen
embryos
transferred
0.0  0.0 0.6  0.9 0.0  0.1 0.5  1.0 0.0  0.3 0.3  0.8
Retrievals with fresh/
frozen ET
45.00% (9/20)a 100.00% (35/35)b 49.29% (69/140)a 75.28% (67/89)c 48.19% (40/83)a 80.60% (54/67)c
Pregnancy rate
(hCGþ/ET)
0.0% (0/9)a 49.0% (25/51)b 7.0% (5/71)a 34.9% (37/106)b,c 7.0% (3/43)a 29.4% (20/68)c
Fresh cycle 0.0% (0/9) 50.0% (17/34) 7.4% (5/68) 29.2% (19/65) 7.5% (3/40) 28.3% (15/53)
Thaw cycle 0.0% (0/0) 47.1% (8/17) 0.0% (0/3) 43.9% (18/41) 0.0% (0/3) 33.3% (5/15)
Biochemical
pregnancy
0 0 2 6 2 3
Ectopic pregnancy 0 0 0 0 0 1
Mors in utero 0 0 0 0 1 0
Miscarriage 0 4 1 9 0 1
Ongoing pregnancy
(>12 wk)
Fresh cycle 0 14 2 12 0 12
Thaw cycle 0 7 0 10 0 3
Live birth rate
(live births/ET)
0.0% (0/9)a 41.2% (21/51)b 2.8% (2/71)a 22.6% (24/106)c 0.0% (0/43)a 22.1% (15/68)c
Fresh cycle 0 14 2 15 0 12
Thaw cycle 0 7 0 9 0 3
Note: Pregnancy rate was deﬁned as the proportion of embryo transfers resulting in a positive hCG test (>10mIU/mL). 2PN¼ two pronuclei; AOA¼ assisted oocyte activation; ET¼ embryo transfer;
ICSI ¼ intracytoplasmic sperm injection; MII ¼ metaphase II; MOAT ¼ mouse oocyte activation test.
a,b,cDifferent superscript letters indicate statistical signiﬁcance between groups (P<.05).
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Fertility and Sterility®MOAT group 3 patients (P¼ .04; Table 1). When evaluating
patients experiencing TFF and LF after ICSI separately, we
observed that fertilization rates after AOA were almost iden-
tical in both patient subgroups, regardless of the MOAT group
(P>.05; Supplemental Table 3).
Overall, one patient in MOAT group 1 and one in MOAT
group 2 with histories of TFF after ICSI still experienced TFF
after AOA treatment. In MOAT group 3, AOA did not result
in any successful oocyte activation in three out of 26 patients
with previous LF and two out of 21 patients with previous TFF
after ICSI (Fig. 1). Furthermore, nine MOAT group 2 patients,
ﬁve with previous LF and four with previous TFF after ICSI,
experienced LF after the application of AOA. Also, eight
MOAT group 3 patients, ﬁve with previous TFF and three
with LF after ICSI, experienced LF after AOA (Fig. 1).
Although outcomes were variable between different ET
policies, some signiﬁcant differences were observed in terms
of embryo quality (categories A and B) among the different
MOAT groups (Fig. 2). Overall, blastocyst rates after AOA
were within the normal range in all MOAT groups (Fig. 2;
Supplementary Table 4). We report on embryo scores forVOL. 112 NO. 2 / AUGUST 2019AOA cycles only, because information regarding embryo
quality from previous ICSI cycles was not provided by most
previous centers.
Overall, all 19 MOAT group 1 patients, 44 of the 56MOAT
group 2 patients, and 37 of the 47 MOAT group 3 patients had
a fresh or frozen ET. Pregnancy rates were signiﬁcantly higher
after AOA (36.4%, 82/225) compared with previous conven-
tional ICSI (6.5%, 8/123; P< .001), increasing signiﬁcantly
from 0.0%, 7.0%, and 7.0% after conventional ICSI to
49.0%, 34.9%, and 29.4% after AOA in MOAT groups 1
(P¼ .006), 2 (P< .001), and 3 (P¼ .005), respectively
(Table 1). When evaluating D2/D3 and D5 ETs separately,
pregnancy rates still increased after AOA compared with pre-
vious ICSI cycles for both groups (Supplemental Table 5). In
total, 14 (17.1%) spontaneous abortions, 9 (11.0%) biochem-
ical pregnancies, and 1 (1.2%) ectopic pregnancy occurred.
Live birth rates were signiﬁcantly higher after AOA
(26.7%, 60/225) compared with previous conventional ICSI
(1.6%, 2/123; P< .001), increasing signiﬁcantly from 0.0%,
2.8%, and 0.0% after conventional ICSI to 41.2%, 22.6%,
and 22.1% after AOA in MOAT groups 1 (P¼ .02), 2269
FIGURE 1
Patient distribution according to the fertilization rates achieved by previous intracytoplasmic sperm injection (ICSI) and subsequent assisted oocyte
activation (AOA) treatment per mouse oocyte activation test (MOAT) group. Patients were distributed into different groups based on their
fertilization rates for both previous conventional ICSI and subsequent AOA cycles. The different categories were: high fertilization (60%–
100%), moderate fertilization (34%–59%), low fertilization (11%–33%), and total failed fertilization (0%–10%).
Bonte. AOA overcomes failed fertilization. Fertil Steril 2019.
ORIGINAL ARTICLE: ASSISTED REPRODUCTION(P< .001), and 3 (P< .001), respectively (Table 1). When eval-
uating D2/D3 and D5 ETs separately, live birth rates also
signiﬁcantly increased after AOA compared with previous
ICSI cycles for both groups (Supplemental Table 5). In total,
21, 21, and 14 clinical pregnancies developed to term in
MOAT groups 1, 2, and 3, respectively (Table 2). Finally, 52
singletons and 4 twins (three twins in MOAT group 2 and
one twin in MOAT group 3) were born. None of the 32 boys
and 28 girls had major or minor congenital malformations.
Only two pregnancies ended up in preterm deliveries: twins
born at 36 weeks 4 days and twins born at 36 weeks, of whichFIGURE 2
Percentages of two-pronuclei (2PN) zygotes that developed into excellent-q
MOAT patients and categorized by the different embryo transfer (ET) polic
timepoint (day 2, 3, and 5). Fractions above the bars indicate the proportion
3; D5 ¼ day 5; other abbreviations as in Figure 1.
Bonte. AOA overcomes failed fertilization. Fertil Steril 2019.
270one twin baby had low weight (2,180 g). Another twin baby
(born at 38 weeks 5 days) also had a slightly lower weight
(2,480 g) (Table 2). Delivery type, birth weight, and Apgar
scores of, respectively, 7, 6, and 13 babies were missing.
Two clinical pregnancies were still ongoing.DISCUSSION
This is the ﬁrst study to describe the efﬁciency of AOA in a
large series of patients with a history of TFF or LF (<33%)
after ICSI, for whom the oocyte-activating capacity of theuality (A) and good-quality (B) embryos after AOA among the different
ies. Every ET policy is subdivided into AþB embryo quality and grading
of 2PNs that developed to AþB quality embryos. D2¼ day 2; D3¼ day
VOL. 112 NO. 2 / AUGUST 2019
TABLE 2
Obstetrical and neonatal outcomes of babies born after assisted
oocyte activation.
Outcome
Singletons
(n[ 52)
Twins
(n[ 4)
Total
(n[ 60)
Obstetrical outcomes
Preterm delivery
(<37 wk)
0 4 4
Vaginal delivery 30 0 30
Cesarean section 15 8 23
Neonatal outcomes
Mean birth
weight (g)
3,556  545 2,825  429 3,435  587
Birth weight
<2,500 g
0 2 2
Apgar score
<7 at 5 min
0 0 0
Perinatal mortality 0 0 0
Sex
Male 27 5 32
Female 25 3 28
Delivery type, birth weight, and Apgar scores of respectively 7, 6, and 13 babies are missing.
Bonte. AOA overcomes failed fertilization. Fertil Steril 2019.
Fertility and Sterility®sperm was examined by means of MOAT. Our data demon-
strate that AOAwith the use of CaCl2 injection in combination
with a twofold ionomycin exposure resulted in signiﬁcantly
higher fertilization, pregnancy, and live birth rates in all
MOAT groups compared with previous ICSI cycles. Patients
with TFF after ICSI had similar outcomes with AOA compared
with patients with LF after ICSI (Supplemental Table 3). These
results conﬁrm earlier ﬁndings reported by our group,
describing an improvement in fertilization rates in all three
MOAT groups in a small series of patients (30 couples, 61
AOA cycles) (8). Moreover, blastocyst rates were within the
normal range in all MOAT groups. Although some patients
underwent multiple AOA cycles, no differences were seen in
AOA outcomes between the ﬁrst AOA cycle for each patient
and all AOA cycles combined.
Except for one globozoospermic patient who still expe-
rienced TFF after AOA, the other 17 patients with globozoo-
spermia showed fertilization rates up to 90% (range
35.0%–89.7%) and pregnancy rates of 49.0%. After AOA,
a high number of two-pronuclei zygotes developed into
excellent- and good-quality embryos. Overall, patients diag-
nosed with a sperm-related OAD responded signiﬁcantly
better to the AOA treatment in terms of fertilization, preg-
nancy, and live birth rates compared with patients with a
suspected oocyte-related OAD.
We report some early spontaneous abortions, but the fre-
quencies were similar to those in other AOA studies (23, 24).
Overall, our ﬁndings show that AOA treatment was a safe
and effective technique resulting in the birth of 60 healthy
babies, conﬁrming earlier safety reports (24–26). However,
continuous follow-up of children born after AOA is
warranted.
Four MOAT 3 patients opted to participate in an oocyte
donation program instead of AOA. Fertilization rates
increased signiﬁcantly from 31.0% (n ¼ 8 cycles; own
oocytes) to 75.0% (n ¼ 8 cycles; donor oocytes; P< .001)VOL. 112 NO. 2 / AUGUST 2019and resulted in the birth of two healthy singletons. These out-
comes further reinforce the importance of performing a diag-
nostic test in patients with fertilization failure after ICSI for
appropriate counseling (8, 18, 27), still lacking in many
centers worldwide. By performing MOAT we are able to: 1)
better predict the success of AOA; 2) provide improved
clinical management, especially regarding gamete donation
in cases when AOA could not overcome fertilization failure;
and 3) diagnose patients with mutations in oocyte
activation-related genes, such as the sperm factor PLCz (espe-
cially inMOAT group 1 and 2 patients), more readily (17). This
is particularly valuable for making patients aware of the
possible risk of transmitting genetic subfertility to their
offspring after AOA. Research has shown that genetic muta-
tions in PLCz have been associated with OAD and fertilization
failure. To date, four missense mutations in the PLCz gene
have been discovered in four different patients experiencing
TFF or LF after ICSI, including H398P, H233L, I489F, and
R197H (28–31). Moreover, mutations in oocyte-related fac-
tors, such as inositol 1,4,5-trisphosphate receptor (IP3R),
Ca2þ/calmodulin-dependent protein kinase II, protein kinase
C, and stromal interaction molecule-1, may also contribute to
OAD, especially in cases where an oocyte-related OAD is sus-
pected (i.e., MOAT group 3) (32). Nevertheless, further
research is required to elucidate the full spectrum of female-
and male-related genes essential for successful fertilization.
Ca2þ ionophore treatment is capable of overcoming not
only sperm-related OADs, but also some suspected oocyte-
related OADs diagnosed by means of MOAT (18). However,
human PLCz has a greater potency to activate mouse oocytes
compared with mouse PLCz (33). Studies have shown that the
sperm of some MOAT group 3 patients can still induce aber-
rant Ca2þ oscillatory patterns in some instances (7, 34).
However, most MOAT 3 patients may have an oocyte-
related OAD due to a defect in the Ca2þ-releasing machinery
of the oocyte, such as IP3R. With the use of MOAT, however,
we investigate only the spermatozoa for their oocyte-
activating capacity.We therefore cannot exclude the possibil-
ity that MOAT group 1 and 2 patients may have an OAD
contributed by both partners. In most cases, this oocyte-
related OAD will also be overcome by AOA (18). Nevertheless,
patients with oocyte-related OADs (i.e., MOAT group 3) may
still experience TFF or LF after AOA, which could be attrib-
uted to several other factors. These may include poor overall
oocyte quality, nuclear defects, defects in the cytoskeleton
associated with store-operated Ca2þ entry, or defects down-
stream of the intracellular Ca2þ-releasing process (18, 32).
Developing further assays to diagnose oocyte-related factors
relating to fertilization will undoubtedly provide improved
clinical management and treatment (32).
The inclusion of a large cohort of patients forms the
strength of this study. However, ICSI cycle data were obtained
from both in-house (25%) and other IVF laboratories (75%).
Therefore, some data remain unknown (e.g., initial indication
for ICSI), and differences in clinical practices, such as ovarian
stimulation protocols, may introduce variability. Because
these data are not readily available from other IVF centers,
we cannot exclude the possibility that some patients may
have beneﬁted from the use of a different stimulation regimen271
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related OAD is suspected (i.e., MOAT group 3). However,
several AOA studies to date face similar potential bias
(35–37). Nevertheless, similar ICSI fertilization rates were
observed in both in-house (11.4%, 32/281) and outside
(15.8%, 254/1,603) cycles (P¼ .06). Although differences in
ET policies may introduce variability, our ﬁndings demon-
strate that pregnancy and live birth rates were higher after
AOA compared with previous ICSI, regardless of whether ET
was performed on D2/D3 or D5 (Supplemental Table 5).
To date, Ca2þ ionophores such as ionomycin and calci-
mycin are the most commonly used chemical activating
agents to overcome fertilization failure after ICSI (3, 4). In
patients with TFF or LF after ICSI, fertilization rates with
the use of calcimycin were much lower (40%–50%) than
those achieved after AOA with the use of ionomycin (up to
70%) (35, 38). Those ﬁndings conﬁrmed our previous results
in mice and humans establishing ionomycin-based oocyte
activation as more efﬁcient (12). Some studies have reported
successful fertilization resulting in healthy live births by
means of strontium chloride (SrCl2) activation in couples
with previous fertilization failure (39, 40). However, its use
and mechanism of action are still controversial, because
Ca2þ oscillations are not observed in human oocytes after
direct exposure to SrCl2 (41, 42). Variability between AOA
protocols and thus AOA outcomes complicates comparisons
of efﬁciency (4). Speciﬁcally, Lu et al. (2018) show that
differences in both ionomycin and Ca2þ concentration in
culture media during AOA can have a negative effect on the
efﬁciency in both mice and humans (42).
Despite the added value of MOAT, more sensitive diag-
nostic tests, such as Ca2þ pattern analysis of the patient's
spermatozoa in mouse (mouse oocyte calcium analysis;
MOCA) or human oocytes (human oocyte calcium analysis;
HOCA) would aid in predicting the success of AOA and guid-
ing further clinical management of fertilization failure after
ICSI (7, 34). Still, these novel diagnostic tests require
specialized equipment and infrastructure, as well as the use
of human oocytes for research, which limits their application.
Because AOA is still an experimental procedure, our ﬁnd-
ings highlight that its use should be reserved for a speciﬁc
subgroup of patients, i.e., those with clear OADs. Patients
who underwent diagnostic testing of the oocyte-activating
potential of spermatozoa before their AOA treatment show
a signiﬁcant improvement in fertilization, pregnancy, and
live birth rates. Importantly, diagnosis is paramount for
improved clinical management and diligent counseling of pa-
tients experiencing failed fertilization after ICSI.
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ORIGINAL ARTICLE: ASSISTED REPRODUCTIONLa activacion asistida de los ovocitos aumenta de manera signiﬁcativa la fecundacion y los resultados gestacionales en pacientes con
un fallo de fecundacion bajo o total despues de la microinyeccion espermatica: un estudio retrospectivo de 17 a~nos
Objetivo: Investigar en que medida la activacion asistida de ovocitos (AOA) mejora los resultados clínicos en pacientes diagnosticados
de deﬁciencia de activacion ovocitaria.
Dise~no: Estudio retrospectivo de cohortes comparando AOA ciclos con ciclos previos con microinyeccion espermatica en parejas que
experimentaron bajo o total fallo de fecundacion tras ICSI. Notablemente, la capacidad de activar el ovocito relacionado con el semen
fue examinada en todos los pacientes antes AOA con el uso de un test de activacion ovocitaria en ratones (MOAT).
Lugar: Centro de infertilidad en un hospital universitario.
Paciente (s): Un total de 122 parejas con historia de bajo o total fallo de fecundacion tras ICSI.
Intervencion (es): ICSI, MOAT, AOA y transferencia embrionaria.
Principales medidas de resultados: Fecundacion, gestacion, y tasas de recien nacidos vivos.
Resultados: MOAT revelo 19 pacientes con OAD (MOAT grupo 1) relacionado con el semen, 56 pacientes con una capacidad de
activacion ovocitaria relacionada con el semen (MOAT grupo 2), y 47 pacientes con una sospecha de OAD relacionada con el semen
(MOAT grupo 3). AOA (191 ciclos) mejoro signiﬁcativamente la fecundacion, gestacion y tasa de recien nacido vivo en todos los grupos
de MOAT comprados con los intentos previos de ICSI (243 ciclos). Las tasas de fecundacion despues de AOA fueron signiﬁcativamente
diferentes entre grupo MOAT 1 (70.1%), 2 (63.0%), Y 3 (57.0%). Entre grupo 1 y 3 de MOAT se observaron diferencias signiﬁcativas en
gestacion (49.0% vs 29.4%) y en tasa de recien nacido vivo (41.2% vs 22.1%). En total, de 225 transferencias embrionarias resultaron 60
ni~nos sanos tras AOA.
Conclusion (es): Pacientes que llevaron a cabo test diagnosticos antes AOA muestran una mejora signiﬁcativa en los resultados clíni-
cos comparado con los ciclos previos. Nuestros hallazgos destacan que AOA debería ser reservado para pacientes con OADs claro.274 VOL. 112 NO. 2 / AUGUST 2019
